GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet ...
The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...
Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system. The approval builds ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Senseonics' Eversense 365 drives 72% Q4 growth as company reclaims U.S. commercialization and targets 65-76% revenue increase in 2026.
Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...
Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...
DUBLIN, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results